-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Longboard Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2020 to Q3 2024.
- Longboard Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$28.1M, a 107% decline year-over-year.
- Longboard Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$87.5M, a 65.3% decline year-over-year.
- Longboard Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$56.8M, a 26.7% decline from 2022.
- Longboard Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$44.8M, a 60.9% decline from 2021.
- Longboard Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$27.8M, a 93.3% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)